• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

血液透析患者中肝素的清除情况。

Heparin elimination in uraemic patients on Haemodialysis.

作者信息

Teien A N, Bjoornson J

出版信息

Scand J Haematol. 1976 Jul;17(1):29-35.

PMID:959771
Abstract

Heparin (100 U/kg bodyweight) was administered as single i.v. injections, and heparin concentration in plasma determined by polybrene titration. Mean concentration half-life was 74.7 min in the normal group (n = 6), 118.6 min in the nephrectomized patients (n = 5), and 97.8 min in the other uraemic patients (n = 6). The differences between the mean values for the normals and for the 2 patient groups were statistically significant (p is less than 0.001 and p approximately 0.2 respectively). Mean anticoagulant half-life (based on thrombin clotting time) was 64.3, 75.8 and 62.7 min in the 3 groups. The differences between heparin concentration half-life and anticoagulant half-life in the 3 groups were statistically significant. These differences may be partly explained by a significant fall in heparin cofactor activity after injection of heparin. There was a strong positive individual correlation between heparin concentration half-life and anticoagulant half-life in the patients (r = 0.94), but not in the normal group (r = 0.31). There was a strong negative individual correlation between heparin tolerance and heparin concentration half-life in the patients (r = -0.84), but no correlation in the normal group. It is concluded that severely impaired renal function has a significant, but moderate influence on heparin elimination.

摘要

以每千克体重100单位静脉注射给予肝素,通过鱼精蛋白滴定法测定血浆中的肝素浓度。正常组(n = 6)的平均浓度半衰期为74.7分钟,肾切除患者(n = 5)为118.6分钟,其他尿毒症患者(n = 6)为97.8分钟。正常组与两组患者的平均值之间的差异具有统计学意义(分别为p < 0.001和p ≈ 0.2)。三组的平均抗凝半衰期(基于凝血酶凝血时间)分别为64.3、75.8和62.7分钟。三组中肝素浓度半衰期与抗凝半衰期之间的差异具有统计学意义。这些差异可能部分是由于注射肝素后肝素辅因子活性显著下降所致。患者中肝素浓度半衰期与抗凝半衰期之间存在强正相关(r = 0.94),但正常组中无此相关性(r = 0.31)。患者中肝素耐受性与肝素浓度半衰期之间存在强负相关(r = -0.84),但正常组中无相关性。结论是,严重受损的肾功能对肝素清除有显著但中等程度的影响。

相似文献

1
Heparin elimination in uraemic patients on Haemodialysis.血液透析患者中肝素的清除情况。
Scand J Haematol. 1976 Jul;17(1):29-35.
2
Heparin elimination in patients with liver cirrhosis.肝硬化患者的肝素清除情况。
Thromb Haemost. 1977 Oct 31;38(3):701-6.
3
Heparin elimination and hemostasis in hemodialysis.血液透析中肝素的清除与止血
Clin Nephrol. 1984 Dec;22(6):303-6.
4
Growth hormone, IGF-I and its binding proteins (IGFBP-1 and -3) in adult uraemic patients undergoing peritoneal dialysis and haemodialysis.接受腹膜透析和血液透析的成年尿毒症患者的生长激素、胰岛素样生长因子-I及其结合蛋白(IGFBP-1和-3)
Clin Endocrinol (Oxf). 2004 Jun;60(6):741-9. doi: 10.1111/j.1365-2265.2004.02049.x.
5
Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.体外循环中肝素的剂量与监测:采用亚临床血浆凝血检测技术的比较
J Thorac Cardiovasc Surg. 1990 Mar;99(3):518-27.
6
Pharmacokinetics and pharmacodynamics of heparin during hemodialysis: interpatient and intrapatient variability.血液透析期间肝素的药代动力学和药效学:患者间和患者内变异性
Pharmacotherapy. 1990;10(5):349-55.
7
Is more heparin necessary for low-dose heparin prophylaxis in uremic patients?尿毒症患者低剂量肝素预防是否需要更多肝素?
Thromb Haemost. 1981 Dec 23;46(4):740-2.
8
Hemodialysis and heparin. Alternative methods of measuring heparin and of detecting activation of coagulation.血液透析与肝素。测量肝素及检测凝血激活的替代方法。
Clin Nephrol. 1991 Jan;35(1):26-33.
9
The effects of three different heparin regimes on heparin concentrations in plasma and fibrin formation in dialyzers.三种不同肝素给药方案对血浆中肝素浓度及透析器中纤维蛋白形成的影响。
Clin Nephrol. 1981 Mar;15(3):135-42.
10
Effect of fibronectin on C3b and Fc receptor-mediated phagocytosis by peripheral blood monocytes in uraemic patients.纤维连接蛋白对尿毒症患者外周血单核细胞C3b和Fc受体介导的吞噬作用的影响。
Nephrol Dial Transplant. 1989;4(1):15-20.

引用本文的文献

1
Pharmacokinetic optimisation of the treatment of deep vein thrombosis.深静脉血栓形成治疗的药代动力学优化
Clin Pharmacokinet. 1997 Feb;32(2):145-72. doi: 10.2165/00003088-199732020-00005.
2
Clinical pharmacokinetics of heparin.肝素的临床药代动力学
Clin Pharmacokinet. 1980 May-Jun;5(3):204-20. doi: 10.2165/00003088-198005030-00002.
3
Heparin pharmacokinetics and pharmacodynamics.肝素的药代动力学和药效学。
Clin Pharmacokinet. 1992 May;22(5):359-74. doi: 10.2165/00003088-199222050-00003.
4
In vitro and in vivo correlation of clotting protease activity: effect of heparin.凝血蛋白酶活性的体外与体内相关性:肝素的影响
Proc Natl Acad Sci U S A. 1977 Jul;74(7):3028-32. doi: 10.1073/pnas.74.7.3028.